KRAS and endometrial carcinoma: In this study, we screened 89 endometrial carcinoma specimens and 12 endometrial carcinoma cell lines for mutations in Akt1 (E17K) and analysed whether AKT1 mutations coexist with any mutations in PTEN, PIK3CA and K-Ras.